OR WAIT null SECS
Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.
February 10, 2016
There was scant praise from the medical community for the eighth and final budget plan from the Obama administration.
February 04, 2016
In a hearing held on Feb. 4, 2016, executives from Valeant and Turing had a hard time explaining their rationales for exorbitant price hikes of older drugs.
February 02, 2016
FDA and industry see progress and challenges in bringing cutting-edge medicines to patients.
February 01, 2016
Can the feds negotiate Medicare Part D prices?
January 29, 2016
FDA and industry seek a more consistent, flexible CMC review process for breakthrough therapies.
January 04, 2016
More “me-betters” and more focused breakthroughs could enhance new drug development.